aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $23.25 Consensus PT from Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have earned a consensus rating of “Hold” from the eight research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $23.25.

ATYR has been the subject of several recent research reports. HC Wainwright lowered shares of aTyr Pharma from a “buy” rating to a “neutral” rating in a report on Monday, September 15th. Cantor Fitzgerald lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research report on Monday, September 15th. Leerink Partners reiterated a “market perform” rating on shares of aTyr Pharma in a research report on Monday, September 15th. Jones Trading lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Finally, Jefferies Financial Group lifted their price target on aTyr Pharma from $9.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 22nd.

Insider Buying and Selling

In other aTyr Pharma news, Director Paul Schimmel bought 317,999 shares of aTyr Pharma stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $0.94 per share, with a total value of $298,919.06. Following the purchase, the director directly owned 1,413,023 shares in the company, valued at $1,328,241.62. This represents a 29.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System purchased a new position in aTyr Pharma during the second quarter valued at $28,000. Y Intercept Hong Kong Ltd acquired a new stake in aTyr Pharma in the 1st quarter worth about $38,000. Ameritas Investment Partners Inc. acquired a new stake in aTyr Pharma in the 2nd quarter worth about $45,000. Legal & General Group Plc purchased a new stake in aTyr Pharma during the 2nd quarter worth approximately $49,000. Finally, XTX Topco Ltd raised its holdings in shares of aTyr Pharma by 74.9% during the first quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock valued at $59,000 after acquiring an additional 8,374 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Trading Down 2.5%

NASDAQ ATYR opened at $0.87 on Friday. The company has a market capitalization of $84.86 million, a price-to-earnings ratio of -1.08 and a beta of 0.79. The company’s 50-day simple moving average is $2.28 and its two-hundred day simple moving average is $3.82. aTyr Pharma has a one year low of $0.68 and a one year high of $7.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). Equities analysts forecast that aTyr Pharma will post -0.91 EPS for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.